No single neurotransmitter causes anxiety. Anxiety arises from the interaction of several chemical messengers in the brain, with GABA, serotonin, norepinephrine, glutamate, and dopamine all playing distinct roles. The most consistent finding across anxiety research is that reduced activity of GABA, the brain’s primary calming chemical, leaves neurons in an overexcited state that makes anxiety more likely. But the full picture involves a web of neurotransmitters that can each tip the balance toward or away from anxious feelings.
GABA: The Brain’s Braking System
GABA (gamma-aminobutyric acid) is the neurotransmitter most directly linked to anxiety. It works by inhibiting neurons, essentially telling them to stop firing. When GABA binds to receptors on a nerve cell, it opens channels that flood the cell with chloride ions, making it unable to fire an electrical signal. This produces a calming effect throughout the brain.
GABA operates in two modes. Fast-acting “phasic” inhibition shuts down neurons immediately at the synapse, like slamming the brakes. A slower, persistent “tonic” inhibition works in the background, keeping neurons generally less responsive to excitatory signals. Both modes are critical for preventing the runaway neural activity associated with anxiety.
Research in the amygdala, the brain’s threat-detection center, demonstrates this clearly. When GABA or drugs that mimic it are delivered directly into the amygdala, fear and anxiety decrease across multiple animal species. When GABA is blocked in the amygdala, anxiety increases. In people with pathological anxiety, the problem may not always be low GABA levels themselves. Changes in the structure of GABA receptors, or shifts in the natural compounds that fine-tune those receptors (particularly neurosteroids), can reduce the brain’s ability to inhibit itself even when GABA is present.
Glutamate: The Accelerator Pedal
If GABA is the brake, glutamate is the gas pedal. It’s the brain’s main excitatory neurotransmitter, and anxiety is increasingly understood as a problem of balance between these two chemicals. Glutamate is actually the biological precursor to GABA, meaning the brain converts glutamate into GABA as needed. When that conversion process falters, the ratio tips toward excitation.
Brain imaging studies have measured this imbalance directly. People with high trait anxiety show elevated glutamate levels in the frontal cortex compared to people with low anxiety. Patients with social anxiety disorder have glutamate levels in the anterior cingulate cortex (a region involved in emotional regulation) that are about 13% higher than those in healthy controls, and the increase correlates with symptom severity. Similar elevations appear in people with PTSD. This is why medications that boost GABA activity work for anxiety: they counterbalance the excess excitatory signaling from glutamate.
Serotonin: A More Complex Role
Serotonin’s relationship with anxiety is less straightforward than popular understanding suggests. Rather than “low serotonin equals anxiety,” the effect depends on which of serotonin’s 14 receptor subtypes are activated. Two subtypes matter most for anxiety: the 1A receptor and the 2A receptor. They have opposite effects. Activating 1A receptors reduces anxiety, while activating 2A receptors increases it. The 2A receptor appears to work partly by suppressing the expression of the calming 1A receptor, creating a feedback loop that can sustain anxious states.
This dual nature helps explain why serotonin-targeting medications can sometimes temporarily worsen anxiety before improving it. SSRIs (selective serotonin reuptake inhibitors) increase serotonin availability across all receptor types. Early on, that means more stimulation of anxiety-promoting 2A receptors. Over weeks, the system adapts, and the net effect shifts toward anxiety relief. SNRIs work similarly but also increase norepinephrine availability, which can provide broader symptom coverage for some people.
Norepinephrine and the Fight-or-Flight Response
Norepinephrine is the neurotransmitter most responsible for the physical symptoms of anxiety: the racing heart, sweaty palms, muscle tension, and hyperalertness. It’s produced primarily in a small brainstem structure called the locus coeruleus, which acts as the brain’s alarm system. When you perceive a threat, even a subtle or unconscious one, the locus coeruleus floods the brain with norepinephrine. Brain imaging shows that even subliminal fear cues (threats you don’t consciously register) activate this region.
Norepinephrine doesn’t work alone. It partners with a stress hormone called CRH (corticotropin-releasing hormone), which also functions as a neurotransmitter in key brain areas including the amygdala. Together, they raise blood pressure, suppress appetite, heighten sensory processing, and shift the body into a state of readiness. In healthy doses, this is the fight-or-flight response that keeps you safe. In anxiety disorders, this system fires too easily or doesn’t shut off. People with PTSD, for instance, show exaggerated heart rate responses, heightened skin conductance, and stronger startle reflexes, all signs of a norepinephrine system stuck in overdrive.
Panic disorder is a dramatic example of this misfiring. Panic attacks involve a sudden surge of sympathetic nervous system arousal, complete with racing heartbeat, chest tightness, and a sense of impending doom, triggered without any actual environmental threat.
Dopamine and Avoidance Behavior
Dopamine’s role in anxiety is less well known but increasingly recognized, particularly in avoidance behavior, the tendency to steer clear of situations that trigger fear. Avoidance is a hallmark of anxiety disorders and one of the main ways anxiety limits daily life. Dopamine circuits connecting the amygdala, the ventral tegmental area, and the nucleus accumbens are central to processing whether you approach or avoid a feared situation.
Animal research shows that dopamine-deficient mice have impaired avoidance responses, and restoring dopamine function specifically in the amygdala and striatum restores normal avoidance behavior. Both D1 and D2 dopamine receptor subtypes in the amygdala appear to be involved. Individual differences in dopamine activity may help explain why some people develop debilitating avoidance patterns while others with similar anxiety levels manage to push through feared situations.
Neuropeptide Y and Stress Resilience
Not all relevant brain chemicals promote anxiety. Neuropeptide Y (NPY) is a naturally occurring compound with powerful anti-anxiety and stress-buffering properties. It directly counteracts CRH, the stress hormone that ramps up the anxiety response. When NPY levels are high, animals and humans cope better with stress. When NPY levels are low, the same stressor produces far more behavioral disruption.
The resilience connection is striking. In animal models of PTSD, the individuals whose behavior was most severely disrupted by stress had the lowest brain NPY levels. Rats engineered to overproduce NPY in the hippocampus were essentially immune to stress-induced anxiety. Even more compelling, administering NPY into the amygdala protected animals from the effects of stress for up to eight weeks. In human combat veterans without PTSD, those who had recovered from a past episode of PTSD showed the highest NPY levels, suggesting that the ability to bounce back from trauma is linked to robust NPY expression.
Why There’s No Simple Test
Given how many neurotransmitters contribute to anxiety, you might expect a blood test or brain scan that could pinpoint the problem. No such test exists. A consensus review of biological markers for anxiety disorders found that despite extensive high-quality research into serotonin, norepinephrine, dopamine, GABA, neuropeptides, and stress hormones, none of these markers is specific or reliable enough to serve as a diagnostic tool. Anxiety disorders are still diagnosed through clinical evaluation of symptoms and their impact on your life.
This isn’t a failure of science so much as a reflection of how complex anxiety actually is. Your particular anxiety may involve more GABA dysfunction, or more norepinephrine reactivity, or more serotonin receptor imbalance, or some combination of all of them. The treatments that work for anxiety reflect this complexity. Benzodiazepines directly enhance GABA receptor function for rapid relief. SSRIs reshape serotonin signaling over weeks. SNRIs target both serotonin and norepinephrine. Each class works on a different piece of the puzzle, which is part of why finding the right treatment sometimes takes trial and adjustment.